Report Highlights
The global market for antibody-drug conjugates is estimated to increase from $10.8 billion in 2023 to reach $47.0 billion by 2029, at a compound annual growth rate (CAGR) of 28.4% from 2024 through 2029.
Report Includes
- 25 data tables and 45 additional tables
- An updated review of the global market for antibody drug conjugates
- Analyses of the global market trends, with data from 2021-2023, estimates for 2024, forecasts for 2025, and projections of compound annual growth rates (CAGRs) through 2029
- Evaluation of the overall market for antibody drug conjugates, and corresponding market share analysis by payload type, linker type, antibody type, indication and region
- Coverage of the latest approvals, recalls, safety alerts, and clinical trials; the technical issues related to human anti-mouse antibody (HAMA); and the factors affecting mAB drugs
- Information about major and emerging technologies for the formulation of antibody drug conjugates and assessment of their relation to biotechnology, immunology, pharmaceuticals, and biodefense companies
- Discussions of the market dynamics, opportunities and challenges
- Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
- Competitive intelligence, including companies’ market shares, recent M&A activity and venture funding
- Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Daiichi Sankyo, Pfizer Inc., and Gilead Sciences
Report Scope
This report focuses on the global market for antibody-drug conjugates (ADCs), offering an updated review that covers their fundamental design and use across different oncology fields. In this report, market segmentation is based on payload, linker, antibody, indications, and region. The report also discusses current and developing technologies, market projections and market shares. An analysis of clinical trials, innovations, opportunities, and the latest trends in the ADC market are also discussed in the report.
The report only covers antibody-drug conjugates in which an antibody is conjugated with small-molecule cytotoxic agents (also called payload) through a linker. Alternative antibody conjugates, such as those involving antibodies linked to radioisotopes, are not covered in this report.
Report Synopsis
| Report Metrics | Details | ||||||
|---|---|---|---|---|---|---|---|
| Base year considered | 2023 | ||||||
| Forecast period considered | 2024-2029 | ||||||
| Base year market size | $10.8 billion | ||||||
| Market size forecast | $47.0 billion | ||||||
| Growth rate | CAGR of 28.4% for the forecast period of 2024-2029 | ||||||
| Units considered | $ Millions | ||||||
| Segments covered | Payload Type, Linker Type, Antibody Type, Indication Type | ||||||
| Regions covered | North America, Europe, Other Regions | ||||||
| Countries covered | U.S., Canada, Mexico, U.K., Germany, France, Poland, Denmark, Japan, China, India, Australia, South Korea, Thailand, Singapore, Vietnam, South America, Middle East Africa | ||||||
| Key Market Drivers |
|
||||||
| Companies studied |
|
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Highlights
The global market for antibody drug conjugates was valued at $1.3 billion in 2016. The market should reach $4.2 billion by 2021, growing at a compound annual growth rate (CAGR) of 25.5% from 2016 to 2021.
Report Includes
- An overview of the global market for antibody drug conjugates as a part of the pharmaceutical industry that is looking for innovative technologies.
- Analyses of global market trends, with data from 2014, 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Examination of key market drivers and challenges.
- Insight into regulatory hurdles and how to meet them, as well as discussion of the drugs (and the companies behind them) that have received approval.
Report Highlights
The global market for ADC drugs reached $179 million in 2012 and $396 million in 2013. The market should reach $2.8 billion in 2018 with a compound annual growth rate (CAGR) of 48.1%.
Report Includes
- An overview of the global market for ADCs as a part of the pharmaceutical industry that is looking for innovative technologies.
- Analyses of global market trends, with data from 2012, 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Examination of key market drivers and challenges.
- Insight into regulatory hurdles and how to meet them, as well as discussion of the drugs (and the companies behind them) that have received approval.
Related Reports
Global Oncology Pharmaceuticals Market
The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.
Antibody Drugs: Technologies and Global Markets
The global market for antibody drugs is expected to grow from $242.6 billion in 2024 and is projected to reach $412.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.2% during the forecast period of 2024 to 2029.
Monoclonal Antibodies for Oncology: Global Markets
The global market for monoclonal antibodies in oncology is estimated to grow from $76.2 billion in 2022 to more than $138.1 billion by 2027, with a compound annual growth rate (CAGR) of 12.6% during the forecast period of 2022-2027.
Biological Therapies for Cancer: Technologies and Global Markets
The global cancer biologics market should reach $143.0 billion by 2026 from $77.5 billion in 2021 at a compound annual growth rate (CAGR) of 13.0% for the forecast period of 2021 to 2026.
Recent Reports
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Active Pharmaceutical Ingredients: Global Markets
The global market for active pharmaceutical ingredients (APIs) is estimated to increase from $247.8 billion in 2023 to reach $347.9 billion by 2029, at a compound annual growth rate (CAGR) of 5.9% from 2024 through 2029.
Global Market for Contract Research Organization (CRO) Services
The global market for contract research organization (CRO) services is expected to grow from $111.8 billion in 2024 and is projected to reach $166.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.
Global Oncology Pharmaceuticals Market
The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.
Excipients in Pharmaceuticals: Global Markets to 2029
The global market for pharmaceutical excipients was valued at $9.2 billion in 2023. It is expected to grow from $9.7 billion in 2024 to $12.4 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2029.
Top Trending Reports
AI in Clinical and Molecular Diagnostics Market
The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.
Point-of-Care Diagnostics: Technologies and Global Markets
The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.
Medical Devices: Technologies and Global Markets
The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
CRISPR Technology: Global Markets
The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.
Global Artificial Intelligence (AI) Market: Investments vs Potential
The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More